At its 2026 Annual Meeting on June 15, 2026, HCW Biologics Inc. stockholders approved an amendment to the certificate of incorporation allowing for one or more reverse stock splits in an aggregate range from 1-for-5 to 1-for-20 to maintain Nasdaq listing compliance. Stockholders also approved the issuance of shares upon exercise of up to 2,477,292 Common Stock Purchase Warrants and the repricing of 3,020,410 existing warrants to an exercise price of $0.6055 per share. Additionally, Lisa M. Giles and Rick S. Greene were elected as Class II directors, and Crowe LLP was ratified as the independent auditor. The company is a biotechnology firm that develops biologic therapies.
